Cambridge Healthtech Institute’s Sixth Annual

Optimisation and Development of Biologics
2-3 November 2015


An exciting range of approaches for biotherapeutics is being introduced all the time, while other products that are less new but equally exciting are under development. Each needs to be optimized throughout development and subjected to rigorous preclinical and clinical testing before being launched as a tried and tested, safe and efficacious product. Big pharma and the larger biotechs have well defined strategies, and all investigators large and small have to focus on doing the right thing at the right time in order to avoid hurdles further down the line.

In this track we would like talks to include a description of the product and/or platform, the mode of action, the benefits the product offers, and challenges encountered and overcome. We are looking for engineering, optimization, preclinical evaluation and, if possible, clinical data for a range of novel biotherapeutics.

We invite presentation proposals on the following and related topics: 

  • Developability assessment strategies: for a range of products such as conjugates, replacement therapies, cytokines, bispecifics, Fc fusions, and/or antibody-based therapeutics

  • Assessment of potential problems:such as PTM and sequence liability, propensity to aggregate, potential manufacturing difficulties etc.

  • Methods for optimising half-life, solubility and stability etc. 

  • Demonstration of safety and efficacy: putting together a good safety package

  • Optimization of manufacturing: manufacturing issues such as ease of transfection, expression levels, yield, purification, purity and scalability

  • Characterisation and impact of product architecture on biological activity 

  • Developments for special delivery: such as in nebulizers, for sub-cutaneous delivery and/or for sustained release

  • Preclinical results and evaluation: development of mouse models, validation, IND enabling studies and plans for entering the clinic

  • Results from the clinic: proof of concept, translational biomarkers, and dose escalation studies


If you would like to submit a proposal to give a presentation at this meeting, please click here.

Deadline for submission is 3 April 2015 

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships. 

For more details on the conference, please contact: 

Nicole Lyscom, Ph.D.
Conference Director
Cambridge Healthtech Institute
Tel: +44 7791 866489
Email: nlyscom@healthtech.com 

For partnering and sponsorship information, please contact: 

Carol Dinerstein,
Director, Business Development
Cambridge Healthtech Institute
Tel: 1 781-972-5471
Email: dinerstein@healthtech.com 

Jason Gerardi
Business Development Manager
Cambridge Healthtech Institute
Tel: 781-972-5452
Email: jgerardi@healthtech.com